Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited covers the period ending January 31, 2019. The document serves as a Corporate Governance Report, updated to reflect the completion of the acquisition of Shire plc on January 8, 2019. Takeda operates as a global pharmaceutical company with a mission to drive innovation in medicine. The report details the company's compliance with the Corporate Governance Code, its capital structure, and its management framework.
Key Financial Metrics and Capital Structure
The filing focuses on governance and capital structure rather than operational financial performance for the period. Specific revenue, profit, or cash flow figures for the reporting period are not provided in this text.
- Capital Structure: Foreign shareholding ratio is more than 30% (as of December 31, 2018).
- Major Shareholder: Following the Shire acquisition, NOMURA BANK LUXEMBOURG S.A. (acting as nominee for Shire shareholders) holds 770,303,013 shares, representing 49.23% of the total share count.
- Other Major Shareholders: Nippon Life Insurance Company (2.63%), The Master Trust Bank of Japan (2.18%), and Japan Trustee Services Bank (1.86%).
- Director Remuneration (FY 2017): Total remuneration for non-Audit Directors was 1,590 million JPY; for Audit and Supervisory Committee Members, it was 126 million JPY.
- Employee Count: More than 1,000 persons (consolidated).
- Sales (FY 2017): More than 1 trillion Yen (consolidated).
Material Changes
The most significant material change reported is the completion of the acquisition of Shire plc on January 8, 2019. This transaction involved the issuance of 770,303,013 new Takeda ordinary shares as part of the consideration. Consequently, the capital structure has shifted, with the nominee for Shire shareholders becoming the largest shareholder.
Additionally, the Board of Directors composition was updated to include three new Independent External Directors (Olivier Bohuon, Ian Clark, and Steven Gillis) who previously served on Shire's board, effective January 2019, to facilitate integration.
Guidance, Outlook, and Governance Commentary
Management Commentary: Takeda is establishing a management framework appropriate for a world-class global pharmaceutical company. The company emphasizes strengthening internal controls, rigorous compliance, and risk management to ensure rapid, sound, and transparent decision-making.
Corporate Governance:
- Board Composition: The Board consists of 15 Directors, 11 of whom are Independent External Directors (a majority). The Board is chaired by an Independent External Director.
- Committees: The company utilizes a Nomination Committee and a Compensation Committee, both chaired by External Directors with a majority of External members, to ensure objectivity.
- Executive Structure: Decision-making authority is delegated to the Takeda Executive Team (TET) and specialized committees (Business Review, Portfolio Review, Audit, Risk and Compliance) to ensure agility.
Risks and Contingencies: The company identifies major potential risks including R&D outcomes, intellectual property rights, patent expirations, side effects, price constraints, foreign exchange fluctuations, and corporate acquisitions. The company maintains a Global Risk Management Policy and a Business Continuity Plan.
Guidance: The filing refers investors to quarterly results and presentation materials on the company website for specific management guidance regarding underlying revenue, Core Earnings, and Underlying Core EPS growth targets.
Important Facts for Investor Verification
- Shire Acquisition Impact: Verify the integration progress and financial impact of the Shire plc acquisition completed in January 2019, which significantly altered the shareholding structure.
- Board Independence: Confirm the ongoing independence of the 11 External Directors, particularly the three new appointees from Shire, to ensure effective oversight during the integration phase.
- Remuneration Policy: Review the Directors' Compensation Policy, which aims to align executive pay with long-term shareholder value through a mix of basic compensation, bonuses, and long-term stock incentives.
- Internal Controls: Assess the effectiveness of the newly emphasized internal control systems, including the Audit and Supervisory Committee and the Global Ethics & Compliance division, in managing post-acquisition risks.
- Financial Targets: Consult the latest quarterly results on the investor relations website for specific numerical guidance on revenue and earnings growth, as this filing does not contain current period financial statements.